What Vivance Pte. Ltd. does

Vivance Pte. Ltd. (formerly AWAK Technologies) is a Singapore-headquartered medical technology company developing devices and digital solutions for chronic kidney disease (CKD) and end-stage renal disease (ESRD). Founded in 2007 and incorporated as AWAK Technologies Pte Ltd, the company rebranded to Vivance in October 2024 to reflect an expanded portfolio built around three core products: Viva Kompact, a ~3kg wearable sorbent-based peritoneal dialysis device that regenerates up to 14 liters of dialysate from 1-2 liters of initial fluid; Viva Komfort, an automated peritoneal dialysis system with point-of-care dialysate generation from tap water that reduces monthly fluid handling weight from approximately 400kg to 45kg; and Viva Konnect, a digital health platform combining a patient app, clinician portal, and the FDA Breakthrough-designated Kidney Disease Progression Prediction (KDPP) AI model built with Ever Fortune.AI.

Underlying the portfolio is patented sorbent-based dialysate regeneration technology that enables miniaturization of the PD device, plus a multi-layered infection management system (UV catheter disinfection, turbidity sensing, integrated peritonitis testing). The KDPP AI was originally developed using China Medical University Hospital (Taiwan) data and externally validated on Mayo Clinic Platform data covering 232,613 stage 3-5 CKD patients, reporting robust discrimination (RRT-AUC 0.85-0.86). Vivance has received two FDA Breakthrough Device Designations (January 2019 for the PD device, November 2023 for the AI model) and operates from offices in Singapore (HQ), Westlake Village, California (regional HQ for US market entry), and Bengaluru, India (R&D center). The company was visited by Singapore's Deputy Prime Minister in 2021 and has approximately 50 employees.

Vivance's intended business model is hardware sales of the wearable and home PD devices, supplemented by licensing or SaaS-style deployment of its AI prediction models through Viva Konnect. All products remain in R&D or pre-pivotal clinical stages and are not commercially available; revenue is therefore pre-commercial. The company is preparing for a US pivotal trial planned to commence in 2025. It has raised more than US$60 million across a US$40 million Series A in December 2019 (co-led by Advanced MedTech and Vickers Venture Partners) and a US$20+ million Series B in September 2023 (co-led by Lion X Ventures and Vickers Venture Partners, with participation from Eckuity Capital). Key strategic and clinical partners include Singapore General Hospital, Mayo Clinic, and Ever Fortune.AI.

Name

Vivance Pte. Ltd.

Legal name

Vivance Pte. Ltd.

Website

https://www.vivance.com

Company type

Private

Operating status

Operating

Short description

Vivance Pte. Ltd., a Singapore-based medical technology company, develops a wearable sorbent-based peritoneal dialysis device (Viva Kompact), a point-of-care dialysate generation system (Viva Komfort), and an AI-powered digital health platform (Viva Konnect) for chronic and end-stage kidney disease patients. Pre-commercial.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Custom Computer Programming Services (541511)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Services-Prepackaged Software (7372)

akta.pro primary industry

Peritoneal Dialysis (PD) Systems & Supplies (HLAHAKAB)

akta.pro secondary industries

Nephrology Telemedicine Platforms (HLALAGAI), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

Keywords

• Wearable dialysis devices
• Peritoneal dialysis systems
• Kidney care technology
• Digital health platforms
• Sorbent-based dialysate regeneration

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Wearable/Portable Dialysis Devices: The company plans to generate revenue through sale of its wearable peritoneal dialysis devices (Viva Kompact and Viva Komfort). Products are currently in R&D stage and not commercially available. The company has received FDA Breakthrough Device Designation and is progressing through clinical trials toward commercialization.
2. AI Prediction Models Licensing: AI-based kidney disease progression prediction models licensed or provided as part of the Viva Konnect digital platform. Collaboration with Ever Fortune.AI for development, with potential for clinical adoption.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Vivance develops a portfolio of kidney care technologies including Viva Kompact, an ultraportable wearable peritoneal dialysis (PD) device using patented sorbent-based dialysate regeneration; Viva Komfort, an automated PD system with point-of-care dialysate generation from tap water; and Viva Konnect, a digital health ecosystem with AI-based kidney disease progression prediction for remote patient monitoring. All products are currently in R&D and clinical trial stages and are not yet commercially available, targeting home-based dialysis for end-stage renal disease patients and healthcare providers.

Product overview

Vivance Pte. Ltd. (formerly AWAK Technologies) offers a comprehensive kidney care portfolio comprising three core products: Viva Komfort (an APD system with on-demand dialysate generation), Viva Kompact (a wearable sorbent-based peritoneal dialysis device), and Viva Konnect (a digital health ecosystem with AI-powered prediction models). The portfolio is designed to address the full spectrum of kidney care from device-based dialysis therapy to digital monitoring and predictive analytics, all aimed at enabling home-based and patient-centric kidney disease management.

Differentiator

Problem solved

Functional benefit

Brands

• Viva Kompact: Breakthrough ultraportable dialysis device designed to offer dialysis anytime, anywhere using patented sorbent-based dialysate regeneration technology. Weighs approximately 3kg, is more than 20 times smaller than existing home dialysis machines, and can be worn, used as handheld, or placed on a bedside table.
• Viva Komfort
• Viva Konnect

Products and services

• Viva Kompact Breakthrough ultraportable wearable peritoneal dialysis device weighing approximately 3kg using patented sorbent-based dialysate regeneration technology. Regenerates 14 liters of PD fluid from just 1-2 liters of initial fluid, enabling dialysis anytime, anywhere with three flexible usage modes: table-top, hand-carry, and wearable. Designed for end-stage renal disease patients needing regular dialysis.
• Viva Komfort Novel automated peritoneal dialysis (APD) system with breakthrough point-of-care PD fluid generation technology that produces dialysis fluid directly from tap water. Reduces storage space by 95% and daily weight handling from 12kg to 0.5kg. Features advanced infection management with UV module for catheter connection disinfection, turbidity detection for infection screening, and integrated peritonitis testing. Designed for peritoneal dialysis patients undergoing home treatment.
• Viva Konnect Digital ecosystem for comprehensive kidney care comprising patient mobile app, clinic portal, and AI-based kidney disease progression prediction models. Enables remote patient monitoring, therapy tracking, medication adherence, vitals monitoring, dietary management, risk factor assessment, and teleconsultation. Designed for chronic kidney disease patients, dialysis patients, nephrologists, dialysis clinics, and hospitals.

Quantifiable outcome

• Reduces dialysis fluid needed by up to 90% through sorbent regeneration
• +10 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Singapore General Hospital (SGH)coreStrategic or Co-development Partner · 20 June 2023Long-standing clinical partnership for conducting First-in-Human trial (2018), pre-pivotal trial (2023), and ongoing research. A/Prof. Marjorie Foo serves as Principal Investigator. Collaboration includes developing new AI models using de-identified CKD patient database and testing existing KDPP model.
• Ever Fortune.AIcoreTechnology or Integration · 1 September 2021Strategic partnership with Taiwan-based AI company (spin-off from China Medical University Hospital) to revolutionize kidney disease diagnosis, treatment, and management using medical big data and artificial intelligence. Led to development of KDPP AI model granted FDA Breakthrough Device Designation.
• Mayo CliniccoreStrategic or Co-development PartnerCollaboration for real-world validation and optimization of CKD progression prediction models using Mayo Clinic Platform data. Analyzed 232,613 stage 3-5 CKD patients from Mayo Clinic sites (AZ, FL, MN) between 2018 and 2024. Validated AI model performance across diverse U.S. cohort.
• China Medical University Hospital (CMUH), TaiwancoreStrategic or Co-development PartnerOriginal development of KDPP AI models using CMUH iHi platform. Dr. Chin-Chi Kuo serves as Medical Consultant of EFAI. Models developed using Taiwan data and validated internationally.
• Kidney Dialysis Foundation (KDF), SingaporeminorOthersCorporate social responsibility partnership. AWAK matched employee donations to fulfill wishes of dialysis patients at KDF. KDF provides subsidized dialysis treatment to needy patients in Singapore. Team participated in GOT TO WALK 2021 fundraiser.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Outset Medical: Outset Medical (Nasdaq: OM) develops the Tablo console-style hemodialysis system for home and acute settings. It is the closest direct peer to Vivance in pursuing compact, simplified home/portable dialysis technology and is materially further along the commercialization path with FDA-cleared, revenue-generating products.
• Quanta Dialysis Technologies: Quanta develops the SC+ portable hemodialysis system targeting home and clinic use with simplified water-supply requirements. Like Vivance, Quanta is pursuing miniaturization and simplification of dialysis delivery to enable broader home adoption, though Quanta focuses on hemodialysis rather than peritoneal.

Broad incumbents

• Medtronic: Medtronic has a renal care portfolio and shares overlap with Vivance's leadership team pedigree (board member Kimberly Oleson spent ~28 years at Medtronic). While not a direct PD competitor, it represents a large MedTech incumbent with the capital and distribution to enter adjacent renal markets.
• Baxter International: Baxter manufactures the HomeChoice and Amia automated PD systems and supplies PD dialysate — directly overlapping with Vivance's Viva Kompact and Viva Komfort. Baxter is the leading PD device and fluids supplier globally and is exposed to the same supply chain risks Vivance aims to solve.
• DaVita: DaVita is the second-largest US dialysis services provider with extensive home dialysis programs and integrated kidney care initiatives (DaVita Integrated Kidney Care). Represents a major incumbent customer/channel for Vivance's devices and a key clinical advisory board participant.
• Fresenius Medical Care: Fresenius is the world's largest dialysis services and products company, operating thousands of clinics and producing a broad portfolio including home hemodialysis (NxStage acquired) and PD systems. It is the dominant incumbent that Vivance must displace or partner with to scale.

Emerging players

• Strive Health: Strive Health is a value-based kidney care company partnering with payers and providers to manage CKD and ESRD populations. Its care model requires the kind of AI risk stratification and remote monitoring that Viva Konnect and KDPP enable, making it a logical commercial partner.
• Somatus: Somatus is a value-based kidney care provider offering integrated CKD/ESRD care to health plans and providers. Its risk-bearing care model aligns with Vivance's KDPP AI-driven proactive management thesis and represents a potential channel partner for Viva Konnect.
• HealthBeacon: HealthBeacon develops connected medication adherence tools and digital therapeutics platforms. It is comparable to Vivance in pursuing connected device + digital health models for chronic conditions, though focused on injectable therapies rather than dialysis.

Regional players

• Biolidics: Biolidics is a Singapore-listed MedTech company developing diagnostic and connected care solutions. Vivance's R&D Director Koh Yau Luong previously led product development at Biolidics, and both companies operate within the Singapore MedTech ecosystem addressing chronic disease management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInsg.linkedin.com/company/awak-technologies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivance Pte. Ltd.